What is William Blair’s Estimate for APLS Q4 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at William Blair reduced their Q4 2026 EPS estimates for Apellis Pharmaceuticals in a research report issued to clients and investors on Tuesday, July 1st. William Blair analyst L. Hanbury-Brown now forecasts that the company will earn $0.00 per share for the quarter, down from their previous forecast of $0.04. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same period in the previous year, the firm posted ($0.54) EPS. The company’s revenue for the quarter was down 3.2% compared to the same quarter last year.

Other equities analysts also recently issued reports about the company. Mizuho reduced their target price on Apellis Pharmaceuticals from $30.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 14th. Raymond James Financial downgraded Apellis Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and lowered their price target for the company from $75.00 to $52.00 in a report on Friday, May 9th. Robert W. Baird dropped their price objective on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an “outperform” rating on the stock in a research note on Thursday, May 8th. Bank of America lowered Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $41.00 to $23.00 in a research report on Friday, May 9th. Finally, Needham & Company LLC decreased their price target on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Nine analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $39.79.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $17.82 on Thursday. Apellis Pharmaceuticals has a 1-year low of $16.10 and a 1-year high of $42.47. The firm has a market cap of $2.24 billion, a PE ratio of -9.96 and a beta of 0.67. The firm has a 50 day simple moving average of $18.13 and a 200-day simple moving average of $23.81. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.08 and a quick ratio of 3.62.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC boosted its position in shares of Apellis Pharmaceuticals by 119.6% during the first quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company’s stock worth $89,173,000 after buying an additional 2,220,977 shares during the period. Boxer Capital Management LLC acquired a new position in Apellis Pharmaceuticals during the 4th quarter worth $45,504,000. National Bank of Canada FI grew its stake in shares of Apellis Pharmaceuticals by 266,361.5% in the fourth quarter. National Bank of Canada FI now owns 1,385,600 shares of the company’s stock worth $44,214,000 after purchasing an additional 1,385,080 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Apellis Pharmaceuticals by 969.6% in the fourth quarter. Royal Bank of Canada now owns 1,518,827 shares of the company’s stock worth $48,465,000 after purchasing an additional 1,376,832 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new position in shares of Apellis Pharmaceuticals during the fourth quarter valued at $41,014,000. Institutional investors own 96.29% of the company’s stock.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $18.77, for a total value of $93,850.00. Following the sale, the general counsel owned 133,730 shares of the company’s stock, valued at $2,510,112.10. This trade represents a 3.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.50% of the stock is owned by corporate insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).